Navigation Links
Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome
Date:11/20/2008

dical need for additional treatment options to combat resistant infections and is the first antibiotic in the dihydrofolate reductase (DHFR) selective inhibitor class to demonstrate efficacy against cSSSIs caused by MRSA. The DHFR class has been proven safe and effective in more than four decades of clinical use.

About Arpida

Arpida (SWX: ARPN) is a biopharmaceutical company headquartered in Reinach, Switzerland with operations in Switzerland and the United States. It focuses on the discovery, development and commercialization of novel drugs for the treatment of microbial infections. Arpida has a fully integrated platform for the discovery and development of drug candidates to address the increasing prevalence of resistance of bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), to existing antibiotic therapies. Arpida is currently developing an iclaprim oral formulation as a step-down therapy after intravenous therapy. Apart from the flagship iclaprim program, Arpida has an innovative antifungal treatment in Phase III clinical development as well as several earlier-stage programs (AR-709 and AR-2474).

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

(i) Centers for Disease Control and Prevention Web site. Healthcare-Associated Methic
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arpida Invited to Present Data on Iclaprim at Scientific Conference
2. Arpida Provides Further Comments on the Pivotal Phase III Trials
3. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
4. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
5. Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
6. Pivotal Phase III Data Confirm the Efficacy and Safety of Arpidas Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
7. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
8. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
9. SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
10. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
11. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015 According to a ... Type (Integrated, Standalone), by Deployment Mode (Web based, On-Premise, ... Healthcare Service Providers), by Component - Global Trends & ... is estimated at $501.1 Million 2014, and is projected ... of 7.6% from 2014 to 2019. ...
(Date:8/27/2015)... 2015  Mytrus, a technology and services company revolutionizing clinical trials, ... consent has received approval for use by ... the first time e-Consent technology will be used in ... Mytrus was also the first electronic informed ... by the U.S. Food and Drug Administration in 2011. ...
(Date:8/27/2015)... Colo. , Aug. 27, 2015  Lightwave ... on the development of Next Generation Photonic ... for applications in high speed fiber-optic data communications ... Michael Lebby has been appointed to the ... reputation in the field of optoelectronics is widely ...
Breaking Medicine Technology:Radiology Information Systems Market Worth $722.7 Million by 2019 2Radiology Information Systems Market Worth $722.7 Million by 2019 3Radiology Information Systems Market Worth $722.7 Million by 2019 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 5Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 6Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 7Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3
... 2011 With the support of Key Opinion Leaders ... the time and attention of KOLs is intensifying. But ... landscape for creating and maintaining KOL and physician relationships. ... KOL landscape, Best Practices, LLC has published an updated ...
... Endo Pharmaceuticals (Nasdaq: ENDP ) announced today ... of President, HealthTronics Inc., effective Aug. 29, 2011. HealthTronics, ... urological products and services based in Austin, Texas. ... HealthTronics Group President James Whittenburg, who is staying through ...
Cached Medicine Technology:Pharma Medical Science Liaison Outreach Shifting Away from Traditional Company Sales Regions 2Endo Pharmaceuticals Announces Leadership Change at HealthTronics Subsidiary: Appoints Kelly Huang, Ph.D. New President 2Endo Pharmaceuticals Announces Leadership Change at HealthTronics Subsidiary: Appoints Kelly Huang, Ph.D. New President 3
(Date:8/28/2015)... Texas (PRWEB) , ... August 28, 2015 , ... Yisrayl ... a new publication and pleads for swift actions to be taken in order ... unnatural disasters. , Yisrayl says scientists have yet to understand fully the real ...
(Date:8/28/2015)... BOSTON, MA (PRWEB) , ... August 28, 2015 ... ... WorldCare International, Inc. ’s online medical consultations result in high percentages of change ... performed by the Center for Healthcare Informatics at Tennessee Tech University and analyzed ...
(Date:8/28/2015)... ... August 28, 2015 , ... On October 3, 2015, BethAnn Telford of TeamBT ... the Grand Canyon with a shared mission: to beat brain cancer. In one grueling ... the canyon, then up to the South Rim over 21.1 miles and more than 10,000 ...
(Date:8/27/2015)... ... ... This new webinar educates providers about how can they create a scalable and ... authorizations are in check, and they are current with their payments. Learn ... Software, growing a practice depends on patient experience and clinician’s relationship with the patient. ...
(Date:8/27/2015)... ... August 27, 2015 , ... In the addiction treatment industry, some ... months later, relapsing and returning again, all at great cost to them and their ... living homes or soon after leaving facilities who claim to have given addicts tools ...
Breaking Medicine News(10 mins):Health News:Wake Up and Smell the Sick Atmosphere Says Yisrayl Hawkins in New Article This Week 2Health News:WorldCare International, Inc. Celebrates Findings of Independent ROI Study 2Health News:Women Athletes Cross the Grand Canyon to Raise Funds for Brain Cancer Research – October 3rd 2Health News:A New Webinar Teaches Chiropractors How to Use Compliance Alerts to Manage Patient Relationships 2Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 2Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 3
... SuperGen, Inc.,(Nasdaq: SUPG ), a pharmaceutical company ... therapies for solid tumors and,hematological malignancies, today announced ... Officer, is scheduled to present at the,Collins Stewart ... the,Mandarin Oriental Hotel in New York City., ...
... July 2 The Female Health Company,(Amex: FHC ... the Russell,Microcap(R) Index after the Russell Investment Group reconstituted ... June 27, 2008., The Russell Microcap(R) Index measures ... of the U.S. equity market. The Russell,Microcap(R) Index includes ...
... Calif. and YOKOHAMA CITY, Japan, July 2 ... technology company,and Tokyo Electron Device Limited (TED), ... of inrevium evaluation board solutions, and,provider of ... the,distribution of Samplify,s patented Prism(TM) signal compression ...
... Medical recently started offering QuadraBloc™, a new and improved version of ... ... 2008 -- AmWay's MagnaBloc™, a long-popular form of pain management, is ... by Gradient Medical., , ,"QuadraBloc has already been released in the ...
... clinicians should understand and consider the economic impact of ... a report appearing in the July/August issue of ... journal of the American Cancer Society. The report says ... clinicians to be aware of the relative costs and ...
... July 1 GoAmerica, Inc. (Nasdaq:,GOAM), a ... professional,interpreter services for deaf, hard-of-hearing, and speech-disabled,persons, ... the nation,s premier sign,language interpreting services firms: ... (VLI), both of which are based in ...
Cached Medicine News:Health News:SuperGen to Present at the Collins Stewart Growth Conference on July 9, 2008 2Health News:The Female Health Company Added to Russell Microcap(R) Index 2Health News:The Female Health Company Added to Russell Microcap(R) Index 3Health News:The Female Health Company Added to Russell Microcap(R) Index 4Health News:Samplify Systems Announces Distribution Agreement With Tokyo Electron Device Limited, Broadening Availability of Signal Compression Technology 2Health News:New MagnaBloc™ Product Available from Gradient Medical 2Health News:Report says clinicians should consider economic impact of new interventions 2Health News:Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nation's Premier Sign Language Interpreting Services Company 2Health News:Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nation's Premier Sign Language Interpreting Services Company 3Health News:Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nation's Premier Sign Language Interpreting Services Company 4Health News:Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nation's Premier Sign Language Interpreting Services Company 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: